Safety Study of Nivolumab to Treat Advanced or Metastatic Non-small Cell Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Nivolumab
Related studies linked through entity extraction aliases.
Immunotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma
- Status
- RECRUITING
- Phase
- PHASE2
Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
- Status
- TERMINATED
- Phase
- PHASE2
Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Trial to Evaluate the Safety and Efficacy of the Combination of the Oncolytic Immunotherapy Pexa-Vec With the PD-1 Receptor Blocking Antibody Nivolumab in the First-line Treatment of Advanced Hepatocellular Carcinoma (HCC)
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV Melanoma
- Status
- COMPLETED
- Phase
- PHASE3
CheckpOiNt Blockade For Inhibition of Relapsed Mesothelioma
- Status
- COMPLETED
- Phase
- PHASE3
Phase I/Ib Study of Nivolumab & Veliparib in Patients With Advanced Solid Tumors & Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1
Phase 1 Study of SF1126 in Combination With Nivolumab in Patients With Advanced Hepatocellular Carcinoma
- Status
- TERMINATED
- Phase
- PHASE1
Nivolumab & Brentuximab Vedotin Consolidation After Autologous SCT in Patients With High-Risk Classical Hodgkin Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer
- Status
- TERMINATED
- Phase
- PHASE2
Nivolumab and Metformin Hydrochloride in Treating Patients With Stage III-IV Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
- Status
- UNKNOWN
- Phase
- PHASE2
A Safety Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Non-small Cell Lung Cancer
- Status
- WITHDRAWN
- Phase
- PHASE3
Combination Therapy With Nivolumab and PD-L1/IDO Peptide Vaccine to Patients With Metastatic Melanoma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Fostering Efficacy of Anti - PD-1 - Treatment: Nivolumab Plus Radiotherapy in Advanced NSCLC
- Status
- COMPLETED
- Phase
- PHASE2
Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Ipilimumab + Nivolumab w/Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Single Agent Chemotherapy +/- Nivolumab in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor
- Status
- TERMINATED
- Phase
- PHASE2
Nivolumab in Prostate Cancer With DNA Repair Defects (ImmunoProst Trial)
- Status
- UNKNOWN
- Phase
- PHASE2